Peptide drugs to fix leaky heart calcium channels in inherited arrhythmia (CPVT)
Rational Design from Cryo-EM Structures of High-Affinity Ryanodine Receptor Ligands Based on Natural Peptides
Creating peptide-based molecules to calm overactive heart calcium channels for people with CPVT and other RyR2-linked arrhythmias.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11121017 on NIH RePORTER |
What this research studies
From my perspective, researchers are using high-resolution cryo-EM pictures of the heart's calcium-release channel (RyR2) to design peptide molecules that bind tightly and stop harmful calcium leaks. They work with natural peptides called calcins as starting points and modify them so they fit the channel better. The team tests these designed peptides in lab experiments and animal models to see if they reduce spontaneous calcium release that can trigger dangerous heart rhythms. If a molecule looks promising, it could move toward safety testing and eventual human trials.
Who could benefit from this research
Good fit: People with catecholaminergic polymorphic ventricular tachycardia (CPVT) or other arrhythmias linked to RYR2 gene mutations would be the most relevant candidates for future therapies developed from this work.
Not a fit: Patients whose arrhythmias arise from unrelated causes (for example, structural heart disease or non-RyR2 channelopathies) would be unlikely to benefit from RyR2-targeted peptides.
Why it matters
Potential benefit: Could lead to targeted drugs that stabilize RyR2 channels and reduce life-threatening ventricular arrhythmias in patients with CPVT and related cardiomyopathies.
How similar studies have performed: Prior lab and animal studies have shown that peptides and small molecules can alter RyR2 activity, but turning those findings into safe, effective human treatments remains largely unproven.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Valdivia, Hector H — University of Wisconsin-Madison
- Study coordinator: Valdivia, Hector H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.